NYSEMKT:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.35 +0.01 (+2.92%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.3650-Day Range N/A52-Week Range N/AVolume89,537 shsAverage Volume383,738 shsMarket Capitalization$26.70 millionP/E RatioN/ADividend YieldN/APrice Target$3.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsSEC FilingsStock AnalysisAnalyst ForecastsChartFinancialsSEC Filings Get IGC Pharma alerts: Email Address IGC Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside962.3% Upside$3.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.92 out of 5 stars 3.5 Analyst's Opinion Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has only been the subject of 1 research reports in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IGC. Previous Next 0.0 Dividend Strength Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IGC. Previous Next 1.8 News and Social Media Coverage News SentimentIGC Pharma has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for IGC Pharma this week, compared to 6 articles on an average week.MarketBeat Follows4 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of IGC Pharma is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGC Pharma is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About IGC PharmaIGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More IGC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGC Stock News HeadlinesSeptember 4 at 10:27 AM | benzinga.comThe Analyst Verdict: IGC Pharma In The Eyes Of 4 ExpertsSeptember 4 at 10:27 AM | finance.yahoo.comIGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…September 4 at 2:07 AM | americanbankingnews.comAscendiant Capital Markets Increases IGC Pharma (NYSEMKT:IGC) Price Target to $3.75August 27, 2024 | msn.comBioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual MeetingAugust 27, 2024 | finance.yahoo.comIGC Announces Results of its 2024 Annual Stockholders MeetingSee More Headlines Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEMKT:IGC CUSIPN/A CIK1326205 Webigcpharma.com Phone(301) 983-0998Fax240-465-0273Employees67Year FoundedN/APrice Target and Rating Average Stock Price Target$3.75 High Stock Price Target$3.75 Low Stock Price Target$3.75 Potential Upside/Downside+962.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,000,000.00 Net Margins-1,252.64% Pretax Margin-1,252.64% Return on Equity-138.75% Return on Assets-110.26% Debt Debt-to-Equity Ratio0.02 Current Ratio1.77 Quick Ratio1.16 Sales & Book Value Annual Sales$1.06 million Price / Sales25.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book3.53Miscellaneous Outstanding Shares75,636,000Free Float61,265,000Market Cap$26.70 million OptionableN/A Beta1.27 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ram Mukunda (Age 65)President, CEO & Director Comp: $755kMs. Claudia Grimaldi (Age 52)VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director Comp: $347kBenysh Qureshi Esq.M.B.A., Director of OperationsMr. Rohit Goel (Age 30)Senior Director of Accounting & Principal Accounting Officer Key CompetitorsCyteir TherapeuticsNASDAQ:CYTTAnixa BiosciencesNASDAQ:ANIXCheckpoint TherapeuticsNASDAQ:CKPTTribute Pharmaceuticals CanadaOTCMKTS:TBUFFAdlai NortyeNASDAQ:ANLView All Competitors IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.4039 at the beginning of the year. Since then, IGC shares have decreased by 12.6% and is now trading at $0.3530. View the best growth stocks for 2024 here. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEMKT:IGC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
